Last update May 13, 2018

G03CA04

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

This is one of the three major estrogens produced in the human body. It only occurs in significant amounts in the placenta during pregnancy.
Indicated in cases of vaginal dryness in postmenopause.
Used topically with trophic effects on vaginal mucosa.

Since the last update date we have not found published data on its excretion in breastmilk.

Estriol is absorbed vaginally. Intravaginal estriol administration increased plasma levels of estriol in women in menopause (Mattsson 1983, Punnonen 1980) and produced only minor modifications of gonadotropin and prolactin levels (Keller 1981). Absorption is minimal, however, plasma levels are very low (1 nanogram/L) and becomes insignificant after the 3rd week (AEMPS 2017). A very similar substance, estradiol, administered vaginally, was also detected in breast milk (Nilsson 1978 ).

Its high percentage of binding to plasma proteins and short life means transfer to milk in significant quantities is unlikely.

Although no problems have been observed in infants whose mothers were taking estrogens, and there is no clear evidence that milk production may decrease, especially outside the neonatal period, using non-hormonal lubricants (creams, gels or ovules) to treat possible vaginal dryness due to hypoestrogenism during breastfeeding may be preferable to topical estrogens.


See below the information of this related product:

  • Estradiol (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

G03CA04 is Estriol (topical use) in ATC Code/s.

Is written in other languages:

Group

G03CA04 belongs to this group or family:

Tradenames

Main tradenames from several countries containing G03CA04 in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 288 daltons
Protein Binding 90 %
Tmax 2 (0.5 - 4) hours
1.65 ± 0.82 hours

References

  1. Stute P. Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief? Arch Gynecol Obstet. 2013 Abstract
  2. Mattsson LA, Cullberg G. Vaginal absorption of two estriol preparations. A comparative study in postmenopausal women. Acta Obstet Gynecol Scand. 1983 Abstract
  3. Keller PJ, Riedmann R, Fischer M, Gerber C. Oestrogens, gonadotropins and prolactin after intra-vaginal administration of oestriol in post-menopausal women. Maturitas. 1981 Abstract
  4. Punnonen R, Vilska S, Grönroos M, Rauramo L. The vaginal absorption of oestrogens in post-menopausal women. Maturitas. 1980 Abstract
  5. Nilsson S, Nygren KG, Johansson ED. Transfer of estradiol to human milk. Am J Obstet Gynecol. 1978 Abstract

Total visits

1,431

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM